Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Auditor change
|
|
Loxo Oncology, Inc. (LOXO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/15/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/15/2019 |
4
| Nanda Nisha (Chief Development Officer) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Disposed/sold 18,896 shares
@ $235, valued at
$4.4M
Disposed/sold 16,983 options to buy
@ $1.184, valued at
$20.1k
Disposed/sold 14,828 options to buy
@ $1.184, valued at
$17.6k
Disposed/sold 4,557 options to buy
@ $3.648, valued at
$16.6k
Disposed/sold 10,861 options to buy
@ $13.67, valued at
$148.5k
Disposed/sold 9,228 options to buy
@ $31.69, valued at
$292.4k
Disposed/sold 14,870 options to buy
@ $27, valued at
$401.5k
Disposed/sold 18,375 options to buy
@ $26.27, valued at
$482.7k
Disposed/sold 12,000 options to buy
@ $43.56, valued at
$522.7k
Disposed/sold 75,000 options to buy
@ $84.88, valued at
$6.4M
Disposed/sold 37,000 options to buy
@ $139.77, valued at
$5.2M
|
|
| 02/15/2019 |
4
| Naider Avi Z. (Director) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Gifted 15,000 shares
@ $0
Disposed/sold 111,843 shares
@ $235, valued at
$26.3M
Disposed/sold 15,625 options to buy
@ $13, valued at
$203.1k
Disposed/sold 7,812 options to buy
@ $20.91, valued at
$163.3k
Disposed/sold 7,812 options to buy
@ $24.18, valued at
$188.9k
Disposed/sold 11,000 options to buy
@ $78.58, valued at
$864.4k
Disposed/sold 8,750 options to buy
@ $180.98, valued at
$1.6M
|
|
| 02/15/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/15/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/15/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/15/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/15/2019 |
4
| Flaherty Keith T. (Director) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Disposed/sold 9,732 shares
@ $235, valued at
$2.3M
Disposed/sold 32,345 options to buy
@ $1.184, valued at
$38.3k
Disposed/sold 68,620 options to buy
@ $1.184, valued at
$81.2k
Disposed/sold 31,459 options to buy
@ $3.648, valued at
$114.8k
Disposed/sold 15,625 options to buy
@ $13, valued at
$203.1k
Disposed/sold 12,500 options to buy
@ $13.67, valued at
$170.9k
Disposed/sold 7,812 options to buy
@ $20.91, valued at
$163.3k
Disposed/sold 7,812 options to buy
@ $24.18, valued at
$188.9k
Disposed/sold 11,000 options to buy
@ $78.58, valued at
$864.4k
Disposed/sold 2,500 options to buy
@ $84.88, valued at
$212.2k
Disposed/sold 8,750 options to buy
@ $180.98, valued at
$1.6M
|
|
| 02/15/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/15/2019 |
4
| Burstein Jennifer (Senior VP of Finance) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Disposed/sold 17,500 options to buy
@ $11.35, valued at
$198.6k
Disposed/sold 28,000 options to buy
@ $26.27, valued at
$735.6k
Disposed/sold 28,000 options to buy
@ $31.69, valued at
$887.3k
Disposed/sold 12,000 options to buy
@ $43.56, valued at
$522.7k
Disposed/sold 40,000 options to buy
@ $84.88, valued at
$3.4M
Disposed/sold 20,000 options to buy
@ $139.77, valued at
$2.8M
|
|
| 02/15/2019 |
4
| Bilenker Joshua H. (President & CEO) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Disposed/sold 162,707 shares
@ $235, valued at
$38.2M
Disposed/sold 30,000 shares
@ $235, valued at
$7.1M
Disposed/sold 27,459 options to buy
@ $1.184, valued at
$32.5k
Disposed/sold 64,471 options to buy
@ $3.648, valued at
$235.2k
Disposed/sold 318,514 options to buy
@ $13.67, valued at
$4.4M
Disposed/sold 142,000 options to buy
@ $31.69, valued at
$4.5M
Disposed/sold 209,000 options to buy
@ $26.27, valued at
$5.5M
Disposed/sold 100,000 options to buy
@ $43.56, valued at
$4.4M
Disposed/sold 300,000 options to buy
@ $84.88, valued at
$25.5M
Disposed/sold 128,000 options to buy
@ $139.77, valued at
$17.9M
|
|
| 01/17/2019 |
4/A
| Van Naarden Jacob (COO) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Exercised 1,541 shares
@ $3.648, valued at
$5.6k
|
|
| 01/17/2019 |
4/A
| Bilenker Joshua H. (President & CEO) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Exercised 7,500 shares
@ $1.184, valued at
$8.9k
|
|
| 01/02/2019 |
4
| Nanda Nisha (Chief Development Officer) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Granted 37,000 options to buy
@ $139.77, valued at
$5.2M
|
|
| 01/02/2019 |
4
| Burstein Jennifer (Senior VP of Finance) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Granted 20,000 options to buy
@ $139.77, valued at
$2.8M
|
|
| 01/02/2019 |
4
| Van Naarden Jacob (COO) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Granted 57,000 options to buy
@ $139.77, valued at
$8M
|
|
| 01/02/2019 |
4
| Bilenker Joshua H. (President & CEO) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Granted 128,000 options to buy
@ $139.77, valued at
$17.9M
|
|
| 01/02/2019 |
3
| Nanda Nisha (Chief Development Officer) has filed a Form 3 on Loxo Oncology, Inc. |
| 12/17/2018 |
4
| Naider Avi Z. (Director) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Bought 725 shares
@ $138.9185, valued at
$100.7k
|
|
| 12/12/2018 |
4
| Van Naarden Jacob (Chief Business Officer) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Sold 400 shares
@ $130.59, valued at
$52.2k
Sold 1,000 shares
@ $132.23, valued at
$132.2k
Sold 900 shares
@ $133.17, valued at
$119.9k
Sold 1,400 shares
@ $134.65, valued at
$188.5k
Sold 500 shares
@ $135.14, valued at
$67.6k
Sold 200 shares
@ $136.48, valued at
$27.3k
Sold 100 shares
@ $137.39, valued at
$13.7k
Sold 400 shares
@ $134.74, valued at
$53.9k
Sold 800 shares
@ $135.92, valued at
$108.7k
Sold 1,759 shares
@ $137.09, valued at
$241.1k
Sold 500 shares
@ $137.73, valued at
$68.9k
|
|
| 12/12/2018 |
4
| Burstein Jennifer (Senior VP of Finance) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Sold 100 shares
@ $130.79, valued at
$13.1k
Sold 400 shares
@ $132.44, valued at
$53k
Sold 100 shares
@ $133.34, valued at
$13.3k
Sold 550 shares
@ $134.71, valued at
$74.1k
Sold 100 shares
@ $136.04, valued at
$13.6k
Sold 200 shares
@ $135.69, valued at
$27.1k
Sold 587 shares
@ $136.98, valued at
$80.4k
Sold 263 shares
@ $137.88, valued at
$36.3k
Sold 100 shares
@ $139.36, valued at
$13.9k
Sold 100 shares
@ $140.48, valued at
$14k
Exercised 1,250 options to buy
@ $11.35, valued at
$14.2k
|
|
| 12/12/2018 |
4
| Bilenker Joshua H. (President & CEO) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Sold 969 shares
@ $130.58, valued at
$126.5k
Sold 2,001 shares
@ $132.09, valued at
$264.3k
Sold 2,104 shares
@ $133, valued at
$279.8k
Sold 2,049 shares
@ $134.31, valued at
$275.2k
Sold 2,377 shares
@ $135.04, valued at
$321k
Sold 400 shares
@ $136.48, valued at
$54.6k
Sold 100 shares
@ $137.39, valued at
$13.7k
Sold 647 shares
@ $134.63, valued at
$87.1k
Sold 1,153 shares
@ $135.76, valued at
$156.5k
Sold 3,393 shares
@ $136.79, valued at
$464.1k
Sold 2,407 shares
@ $137.63, valued at
$331.3k
|
|
| 11/28/2018 |
4
| Van Naarden Jacob (Chief Business Officer) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Sold 1,556 shares
@ $151.71, valued at
$236.1k
Sold 1,644 shares
@ $152.49, valued at
$250.7k
Sold 1,500 shares
@ $154, valued at
$231k
Sold 600 shares
@ $155.3, valued at
$93.2k
Sold 200 shares
@ $156.45, valued at
$31.3k
Sold 949 shares
@ $138.08, valued at
$131k
Sold 1,170 shares
@ $138.83, valued at
$162.4k
Sold 300 shares
@ $140.13, valued at
$42k
Sold 500 shares
@ $141.69, valued at
$70.8k
Sold 500 shares
@ $143.08, valued at
$71.5k
Sold 200 shares
@ $143.92, valued at
$28.8k
|
|
| 11/28/2018 |
4
| Burstein Jennifer (Senior VP of Finance) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Sold 500 shares
@ $151.57, valued at
$75.8k
Sold 250 shares
@ $152.39, valued at
$38.1k
Sold 100 shares
@ $153.3, valued at
$15.3k
Sold 300 shares
@ $155.13, valued at
$46.5k
Sold 100 shares
@ $156.04, valued at
$15.6k
Sold 200 shares
@ $137.89, valued at
$27.6k
Sold 350 shares
@ $138.95, valued at
$48.6k
Sold 200 shares
@ $140.94, valued at
$28.2k
Sold 200 shares
@ $143.84, valued at
$28.8k
Sold 100 shares
@ $147.09, valued at
$14.7k
Sold 100 shares
@ $148.2, valued at
$14.8k
|
|
| 11/28/2018 |
4
| Bilenker Joshua H. (President & CEO) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Exercised 8,514 shares
@ $3.648, valued at
$31.1k
Sold 800 shares
@ $150.99, valued at
$120.8k
Sold 3,655 shares
@ $152.04, valued at
$555.7k
Sold 1,995 shares
@ $152.75, valued at
$304.7k
Sold 676 shares
@ $154.07, valued at
$104.2k
Sold 2,210 shares
@ $155.08, valued at
$342.7k
Sold 664 shares
@ $156.2, valued at
$103.7k
Sold 2,329 shares
@ $137.92, valued at
$321.2k
Sold 2,638 shares
@ $138.94, valued at
$366.5k
Sold 700 shares
@ $140.14, valued at
$98.1k
Sold 690 shares
@ $141.48, valued at
$97.6k
|
|
| 10/05/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2018 |
4
| Burstein Jennifer (Senior VP of Finance) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Sold 590 shares
@ $165.5278, valued at
$97.7k
Sold 100 shares
@ $167.1, valued at
$16.7k
Sold 560 shares
@ $168.9723, valued at
$94.6k
Sold 539 shares
@ $161.2155, valued at
$86.9k
Sold 311 shares
@ $162.5366, valued at
$50.5k
Sold 200 shares
@ $164.25, valued at
$32.9k
Sold 200 shares
@ $165.05, valued at
$33k
Exercised 1,250 options to buy
@ $11.35, valued at
$14.2k
Exercised 1,250 options to buy
@ $11.35, valued at
$14.2k
|
|
| 10/05/2018 |
4
| Bilenker Joshua H. (President & CEO) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Exercised 10,000 shares
@ $3.648, valued at
$36.5k
Sold 2,905 shares
@ $165.0058, valued at
$479.3k
Sold 1,225 shares
@ $165.9477, valued at
$203.3k
Sold 673 shares
@ $167.0908, valued at
$112.5k
Sold 1,297 shares
@ $168.2902, valued at
$218.3k
Sold 3,705 shares
@ $169.003, valued at
$626.2k
Sold 195 shares
@ $169.6779, valued at
$33.1k
Sold 1,700 shares
@ $160.6138, valued at
$273k
Sold 1,553 shares
@ $161.4096, valued at
$250.7k
Sold 3,152 shares
@ $162.6041, valued at
$512.5k
Sold 2,000 shares
@ $163.6428, valued at
$327.3k
|
|
| 10/03/2018 |
4
| Kunkel Lori Anne (Director) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Sold 4,500 shares
@ $170.1958, valued at
$765.9k
Sold 500 shares
@ $171.896, valued at
$85.9k
Exercised 5,000 options to buy
@ $3.648, valued at
$18.2k
|
|
| 09/14/2018 |
4
| Burstein Jennifer (Senior VP of Finance) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Sold 550 shares
@ $166.1391, valued at
$91.4k
Sold 200 shares
@ $167.25, valued at
$33.5k
Sold 200 shares
@ $168.785, valued at
$33.8k
Sold 300 shares
@ $170.95, valued at
$51.3k
Sold 750 shares
@ $165.5267, valued at
$124.1k
Sold 500 shares
@ $166.756, valued at
$83.4k
Exercised 1,250 options to buy
@ $11.35, valued at
$14.2k
Exercised 1,250 options to buy
@ $11.35, valued at
$14.2k
|
|
| 09/14/2018 |
4
| Bilenker Joshua H. (President & CEO) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Sold 700 shares
@ $164.1594, valued at
$114.9k
Sold 3,700 shares
@ $165.1821, valued at
$611.2k
Sold 2,400 shares
@ $166.4875, valued at
$399.6k
Sold 1,800 shares
@ $167.3814, valued at
$301.3k
Sold 800 shares
@ $168.5125, valued at
$134.8k
Sold 200 shares
@ $169.8872, valued at
$34k
Sold 400 shares
@ $171.075, valued at
$68.4k
Sold 5,636 shares
@ $165.425, valued at
$932.3k
Sold 3,402 shares
@ $166.523, valued at
$566.5k
Sold 962 shares
@ $167.3169, valued at
$161k
Exercised 10,000 options to buy
@ $1.184, valued at
$11.8k
|
|
| 09/14/2018 |
4
| Van Naarden Jacob (Chief Business Officer) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Sold 756 shares
@ $164.4383, valued at
$124.3k
Sold 1,885 shares
@ $165.3156, valued at
$311.6k
Sold 1,059 shares
@ $166.738, valued at
$176.6k
Sold 1,000 shares
@ $167.392, valued at
$167.4k
Sold 200 shares
@ $168.785, valued at
$33.8k
Sold 600 shares
@ $171.0267, valued at
$102.6k
Sold 2,700 shares
@ $165.4463, valued at
$446.7k
Sold 1,500 shares
@ $166.6347, valued at
$250k
Sold 300 shares
@ $167.4867, valued at
$50.2k
Exercised 5,500 options to buy
@ $3.648, valued at
$20.1k
Exercised 4,500 options to buy
@ $3.648, valued at
$16.4k
|
|
| 08/15/2018 |
4
| Van Naarden Jacob (Chief Business Officer) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Sold 730 shares
@ $157.6155, valued at
$115.1k
Sold 3,070 shares
@ $158.6619, valued at
$487.1k
Sold 1,500 shares
@ $159.6893, valued at
$239.5k
Sold 200 shares
@ $160.595, valued at
$32.1k
Sold 600 shares
@ $159.082, valued at
$95.4k
Sold 3,199 shares
@ $159.907, valued at
$511.5k
Sold 701 shares
@ $160.6997, valued at
$112.7k
Exercised 5,500 options to buy
@ $3.648, valued at
$20.1k
Exercised 4,500 options to buy
@ $3.648, valued at
$16.4k
|
|
| 08/15/2018 |
4
| Burstein Jennifer (Senior VP of Finance) has filed a Form 4 on Loxo Oncology, Inc.|
Txns:
| Sold 800 shares
@ $158.0025, valued at
$126.4k
Sold 440 shares
@ $158.6882, valued at
$69.8k
Sold 10 shares
@ $160.17, valued at
$1.6k
Sold 450 shares
@ $159.4656, valued at
$71.8k
Sold 800 shares
@ $160.6488, valued at
$128.5k
Exercised 1,250 options to buy
@ $11.35, valued at
$14.2k
Exercised 1,250 options to buy
@ $11.35, valued at
$14.2k
|
|
|
|
|